



REMINDER

J007 Rec'd PCT/PTO 29 AUG 2005

PET

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	10/539,936	RECEIVED CENTRAL FAX CENTER MAR 06 2008
	Filing Date	June 16, 2005	
	First Named Inventor	Gregory BASARAB	
	Art Unit	Not yet assigned	
	Examiner Name	Not yet assigned	
	Attorney Docket Number	100909-1P US	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 11/30/2005. OMB 0851-0035
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint Lucy Clare Padgel (Limited Recognition No.: L0074),
 Christine Catherine McCormack (Limited Recognition No.: L0065), Carol
 Loeschorn, Reg. No.: 35,590, and Heidi Berven, Reg. No.: 48,951.

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with
 Customer Number:

44992

☐ Firm or Individual Name AstraZeneca Pharmaceuticals LP

Address Global Intellectual Property
 35 Gatehouse Drive

City Waltham

Country USA

State

MA

Zip

02451

Telephone (781) 839-4000

Fax

(781) 839-4500

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
 Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/98)

SIGNATURE of Applicant or Assignee of Record

Signature *T. Bryant*

Name Tracey Bryant

Date 16-August-2005

Telephone

+44 1625 513228

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of 1 forms are submitted.



REMINDER

RECEIVED
CENTRAL FAX CENTER

MAR 06 2008

PTO/SB/98 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Gregory BASARAB, Joseph EYERMANN, Madhusudhan
GOWRAVARAM, Oluyinka GREEN, Lawrence MACPHERSON, Marshall
MORNINGSSTAR and Thanh NGUYEN

Applicant/Patent Owner: _____

Application No.: _____

10/559,936

Filed: _____

June 16, 2005

PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT
OF H. PYLORI INFECTION

Entitled: _____

AstraZeneca AB

(Name of Assignee)

Corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is _____ %

In the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

16-August-2005

Date

Tracey Bryant

Printed or Typed Name

+44 1625 513228

Telephone Number

Authorized Signer for Assignee

Title: Patent Director, Oncology